Zura Bio
Zura Bio
ZURA
NASDAQ
1.12
USD
3.70%
About
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 303.9K |
| Three Month Average Volume | 6.5M |
| High Low | |
| Fifty-Two Week High | 7.6339 USD |
| Fifty-Two Week Low | 2 USD |
| Fifty-Two Week High Date | 06 Sep 2023 |
| Fifty-Two Week Low Date | 22 Mar 2024 |
| Price and Volume | |
| Current Price | 4.13 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 7.40% |
| Thirteen Week Relative Price Change | -26.50% |
| Twenty-Six Week Relative Price Change | 2.35% |
| Fifty-Two Week Relative Price Change | -52.09% |
| Year-to-Date Relative Price Change | -25.32% |
| Price Change | |
| One Day Price Change | -1.20% |
| Thirteen Week Price Change | -21.33% |
| Twenty-Six Week Price Change | 12.53% |
| Five Day Price Change | 15.69% |
| Fifty-Two Week Price Change | -39.97% |
| Year-to-Date Price Change | -11.56% |
| Month-to-Date Price Change | 4.56% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.36098 USD |
| Book Value Per Share (Most Recent Quarter) | 2.4578 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.36098 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.4578 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.76281 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.09421 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.49442 USD |
| Normalized (Last Fiscal Year) | -2.09421 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.09421 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.49442 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.09421 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.49442 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.28946 USD |
| Cash Per Share (Most Recent Quarter) | 2.95904 USD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.19145 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.4725 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 87.09% |
| EPS Change (Trailing Twelve Months) | 87.64% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -186,079,000 |
| Net Debt (Last Fiscal Year) | -98,816,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 2 |
| Long Term Debt to Equity (Most Recent Quarter) | 2 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 13 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,054,000 |
| Free Cash Flow (Trailing Twelve Months) | -25,490,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 2 |
| Total Debt to Equity (Most Recent Quarter) | 2 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -49.98% |
| Return on Assets (Trailing Twelve Months) | -23.00% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -71.73% |
| Return on Equity (Trailing Twelve Months) | -24.79% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -60.56% |
| Return on Investment (Trailing Twelve Months) | -30.30% |
| Return on Investment (5 Year) | -99,999.99% |